Clinical trials: Midazolam
Biological Availability
Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam
Quantify the effect of a probe CYP3A4 inducer (Rifampicin) on the pharmacokinetics of levonorgestrel, norethindrone, desogestrel, dienogest, drospirenone,estradiol and midazolam
- Trial name
- NCT03353857
- Testing
- levonorgestrel/ Microlut, Norethindrone/ Noriday, Desogestrel/ Cerazette
- Where
- 2 sites in Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Bayer
Cataract
A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)
The primary purpose of the study is to evaluate the efficacy and safety of MELT-300 (Midazolam and Ketamine Sublingual Tablets) and the contribution of midazolam and ketamine components to sedation and during the surgery or…
- Trial name
- NCT05133518
- Testing
- MELT-300, Midazolam alone, Ketamine alone
- Where
- 3 sites in United States
- Volunteers
- 338 people
- Sponsor
- Melt Pharmaceuticals
Neoplasms, Breast
To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients
To characterize the effect of repeat oral dose of lapatinib treatment on the pharmacokinetics of a single oral and single intravenous dose of midazolam in adult cancer patients.
- Trial name
- NCT00258050
- Testing
- Midazolam, Lapatinib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Healthy
A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood
In order to assess the potential impact of steady state BI 425809 on CYP3A clinically, the effect of BI 425809 on the midazolam pharmacokinetics will be evaluated. Midazolam is a recommended substrate of CYP3A4.
- Trial name
- NCT05258110
- Testing
- midazolam, iclepertin (BI 425809)
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteer
THE EFFECT OF MULTIPLE DOSES OF PF-06835919 ON THE PHARMACOKINETICS OF A SINGLE ORAL MIDAZOLAM DOSE IN HEALTHY PARTICIPANTS
This is a Phase 1, randomized, open label, 2 way crossover drug drug interaction (DDI) study which will evaluate the impact of PF 06835919 on midazolam pharmacokinetics in healthy participants.
- Trial name
- NCT03916406
- Testing
- PF 06835919, Midazolam
- Where
- Belgium
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cardiovascular Disease
A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects
In clinical practice, AZD5718 will be co-administered with CYP3A substrates. Therefore, it is important to determine the impact of AZD5718 on the pharmacokinetics (PK) of CYP3A4 substrates.
- Trial name
- NCT04492709
- Testing
- Midazolam, AZD5718
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Bioavailability Study of Midazolam Administered as a Solution by Conventional Syringe or ZENEO®
Primary objective of this study is to describe the plasma pharmacokinetics of midazolam after single intramuscular injection on bare skin in the thigh by the needle-free injector Zeneo® compared to injection on bare skin in the…
- Trial name
- NCT05026567
- Testing
- 2 ml of DORMICUM® Midazolam Hydrochloride (15 mg/3 mL), ZENEO® Midazolam (10 mg/0.625 mL) on bare skin in thigh, ZENEO® Midazolam (10 mg / 0.625 mL) on bare skin in ventrogluteal area
- Where
- South Africa
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Crossject
Healthy
Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin
To assess the influence of different dose strengths of BI 1181181 on single dose kinetics of midazolam (CYP3A4 probe drug), warfarin (CYP2C9 probe drug), omeprazole (CYP2C19 probe drug) and digoxin (P-gp probe drug)
- Trial name
- NCT02345304
- Testing
- Omeprazole, Warfarin, BI 1181181
- Where
- Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Drug Reactions
Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes
This study will help determine which types of drugs that may interact with Lu AF35700
- Trial name
- NCT03195946
- Testing
- Lu AF35700, Midazolam, Cocktail of CYP450 substrates
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Advanced Solid Tumor
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
This is an open-label study in advanced solid tumor patients to determine if entrectinib affects the pharmacokinetics of midazolam and any of its pharmacologically active metabolites.
- Trial name
- NCT03330990
- Testing
- Entrectinib, Midazolam Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Healthy
Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Midazolam in Healthy Male Volunteers
The objective of the study was to investigate the effect of BIRT 2584 XX and its metabolite BI 610100 when BIRT 2584 XX is administered as a tablet to near steady state in estimated high therapeutic dose on the pharmacokinetics…
- Trial name
- NCT02256748
- Testing
- BIRT 2584 XX, Midazolam
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Mechanically Ventilated and Intubated Subjects
A Safety and Efficacy Study of Dexmedetomidine in ICU Patients Requiring Continuous Sedation
The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine in ICU subjects who are initially intubated, mechanically ventilated and require sedation for beyond 24 hours.
- Trial name
- NCT00216190
- Testing
- Dexmedetomidine HCL Injection, Midazolam Injection
- Where
- 96 sites in United States, Argentina and 3 more
- Volunteers
- 420 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Healthy
Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults
The purpose of this study is to investigate the potential for cytochrome P450 (CYP) 3A4 induction after dosing with INDV-2000 via use of midazolam as a probe.
- Trial name
- NCT05694533
- Testing
- INDV-2000, Midazolam
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Steatohepatitis, Nonalcoholic, Osteo Arthritis
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine
This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK)…
- Trial name
- NCT07873229
- Testing
- ECC0509, Metformin, Caffeine
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eccogene
Healthy Adult Participants
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
The objective of this study is to evaluate the effect of multiple doses of vorasidenib on single-dose PK of bupropion as an index substrate of CYP2B6, flurbiprofen as an index substrate of CYP2C9, omeprazole as an index substrate…
- Trial name
- NCT07235748
- Testing
- Vorasidenib, Bupropion, Flurbiprofen
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Institut de Recherches Internationales Servier (I.R.I.S.)
Sedation
Multiple Dose Safety and Efficacy Study Evaluating CNS 7056 Versus Midazolam in Patients Undergoing Colonoscopy
The purpose of this dose-response study is to assess the safety and efficacy of CNS 7056 compared with midazolam to maintain suitable sedation levels in patients undergoing colonoscopy.
- Trial name
- NCT01145222
- Testing
- A. CNS 7056, B. CNS 7056, C. CNS 7056
- Where
- 9 sites in United States
- Volunteers
- 162 people
- Sponsor
- Paion UK Ltd.
Chronic Hepatitis B
A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers
This is a drug-drug interaction study conducted in healthy volunteers to evaluate the effect of HRS5091 on CYP3A4, CYP2C9, CYP2C19, P-gp, BCRP and OATP1B1, using midazolam, s-warfarin, omeprazole, digoxin and rosuvastatin as…
- Trial name
- NCT05273775
- Testing
- HRS5091 Tablets, Midazolam Maleate Tablets, Warfarin Sodium Tablets
- Where
- China
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Drug-Drug Interaction, Heathy Volunteer
Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity
Primary objective: 1. To assess the potential inhibitory and inducing effect of oral givinostat on the single dose pharmacokinetics (PK) of intravenous or oral midazolam. 2.
- Trial name
- NCT05492318
- Testing
- Givinostat 10 mg/mL, Midazolam 1mg/ml IV, Midazolam 2.5 mg oromucosal solution
- Where
- Portugal
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Italfarmaco
Rheumatoid Arthritis
Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin
Drug-drug interaction study in healthy men and women not of childbearing potential. Assess the effect of BMS-986195 on the pharmacokinetics of methotrexate, caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and…
- Trial name
- NCT03131973
- Testing
- BMS-986195, Methotrexate, Leucovorin
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy, Pharmacokinetics of ASP015K and Midazolam
A Study to Assess Drug Interaction of ASP015K and Midazolam
The objective of the study is to characterize the effect of multiple doses of ASP015K on the pharmacokinetics of a single dose of midazolam.
- Trial name
- NCT01182077
- Testing
- ASP015K, Midazolam
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc